ABCL vs MEDP
AbCellera Biologics Inc. vs Medpace — AI-powered side-by-side comparison
ABCL
AbCellera Biologics Inc.
64
Buy
VS
| Metric | ABCL | MEDP |
|---|
| AI Score |
64
|
64
|
| Price |
$10.35
|
$596.78
|
| P/E Ratio |
-18.07×
|
34.82×
|
| ROE |
-15.1%
|
98.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.0%
|
28.8%
|
| Debt / Equity |
0.15×
|
0.28×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
90.0
|
72.1
|
| Beta |
1.191
|
1.151
|
| Expected Upside |
—
|
+3.0%
|
AI Committee View
Current Innellis committee reasoning for ABCL versus MEDP.
The committee scores are tied.
ABCL and MEDP both score 64/100.
ABCL Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Revenue growing 101.3% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- ROE of only -17.5% -- cheap may mean cheap for a reason — Value
- RSI at 90 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
MEDP Committee View
67% agreement
6 analysts
The primary driver is eps growing 26.8% yoy. The main limiting factor is p/e of 34.2 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 110.1% shows genuine earnings power backing the valuation — Value
- EPS growing 26.8% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 34.2 is moderate-to-rich — Value
- Price-to-book of 34.5x prices in significant intangible value — Value
- RSI at 72 is in overbought territory — Technical